Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. France
  4. Euronext Paris
  5. Ipsen
  6. News
  7. Summary
    IPN   FR0010259150

IPSEN

(IPN)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector newsMarketScreener Strategies

Ipsen : Q1 Sales Climb 6% Despite COVID-19 Impact

04/22/2021 | 04:59am EDT


© MT Newswires 2021
All news about IPSEN
06/18IPSEN  : A year-long partnership with the ISPC
PU
06/17IPSEN  : launches Perspectives Matter around World Kidney Cance...
PU
06/14ISPRM 2021 : New Ipsen analysis highlights potential treatment gap in adults liv..
AQ
06/11IPSEN  : Finds Potential Treatment Gap Among Spasticity Patients in US
MT
06/11IPSEN  : ISPMR 2021 – 11 June 2021.pdf
PU
06/07IPSEN  : Exelixis Say Phase 3 Trial of Cabozantinib Drug in Differentiated Thyro..
MT
06/07IPSEN  : Exelixis COSMIC-311 ASCO – 7 June 2021.pdf
PU
06/05IPSEN  : World Environment Day 2021
PU
05/31TODAY'S ANALYST RECOMMENDATIONS : Advanced Micro Devices, AstraZeneca, Bodycote,..
05/31IPSEN  : US FDA Accepts Ipsen's Approval Request For Ultra-Rare Genetic Disorder..
MT
More news
Financials
Sales 2021 2 737 M 3 260 M 3 260 M
Net income 2021 542 M 645 M 645 M
Net Debt 2021 83,7 M 99,7 M 99,7 M
P/E ratio 2021 13,5x
Yield 2021 1,16%
Capitalization 7 303 M 8 701 M 8 698 M
EV / Sales 2021 2,70x
EV / Sales 2022 2,56x
Nbr of Employees 5 703
Free-Float 41,9%
Chart IPSEN
Duration : Period :
Ipsen Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends IPSEN
Short TermMid-TermLong Term
TrendsBullishBullishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 17
Average target price 91,03 €
Last Close Price 88,30 €
Spread / Highest target 28,0%
Spread / Average Target 3,09%
Spread / Lowest Target -15,1%
EPS Revisions
Managers and Directors
NameTitle
David G. Loew Chief Executive Officer & Director
Aymeric Le Chatelier Chief Financial Officer & Executive Vice President
Marc M. P. de Garidel Non-Executive Chairman
Aidan Murphy Executive Vice President-Technical Operations
Howard Mayer Executive Vice President-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IPSEN30.04%8 747
JOHNSON & JOHNSON4.10%426 557
ROCHE HOLDING AG12.70%325 803
PFIZER, INC.7.09%217 246
NOVARTIS AG2.47%208 642
ABBVIE INC.7.07%199 795